The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS 680 Employees Exit Takeda in Buyout Program, 10%-Plus of Japan Staff
March 4, 2025
-
REGULATORY No Prior Talks with US Drug Makers for Deferred PMP Price Cuts: Health Minister
March 3, 2025
-
REGULATORY J&J’s Lazcluze, Genmab’s Tivdak and More Drugs in Line for Japan Approval
February 28, 2025
-
ORGANIZATION JPMA President Demands Rethink of Social Security Expenditure Cap
February 27, 2025
-
ORGANIZATION Japan Pharma Lobbies Likely to Enter Yasukawa/Miyabashira Era toward FY2026 Reform
February 26, 2025
-
ACADEMIA 1st CP Inhibitor Approved for Sarcoma, Could This Be a Breakthrough to Treatment of More Subtypes?
February 25, 2025
-
REGULATORY Japan Approves CSL’s HAE Med Andembry, Tecentriq Sarcoma Use, and More
February 21, 2025
-
REGULATORY Pfizer Pulls Japan NDA for Hemophilia Gene Therapy Beqvez as Program Called Off Globally
February 20, 2025
-
BUSINESS LTL Pharma Sees 30% Drop in Gaster Sales after New LLP Coverage Rollout
February 19, 2025
-
REGULATORY Espha’s Januvia Generic on Approval Roster towards June Listing
February 18, 2025
-
REGULATORY Japan to Approve EquMet Generics, More Copycats toward June Listing
February 17, 2025
-
REGULATORY J&J’s Lazcluze, Genmab’s Tivdak, and More Up for MHLW Panel Review on Feb. 27
February 14, 2025
-
BUSINESS Regeneron to Upsize Japan Workforce after Libtayo Transfer
February 13, 2025
-
BUSINESS Cheplapharm Set to Expand LLP Deals to 20 APIs, Sees Opportunities Despite Headwinds
February 12, 2025
-
ORGANIZATION US Lobbies Send Letters of Protest to Japan Embassy over Off-Year Revision, CEA
February 10, 2025
-
BUSINESS Bain Picks Up Mitsubishi Tanabe for Over 500 Billion Yen
February 10, 2025
-
BUSINESS AstraZeneca Looks to Keep No.1 Spot in Japan Oncology Space, Driven by Bispecific Antibodies
February 7, 2025
-
BUSINESS Celltrion Set for 6 Biosimilar Filings in 2 Years, Sees Japanese Data Waiver as a Boon
February 6, 2025
-
REGULATORY Japan’s 1st Hemophilia B Gene Therapy Up for Panel Review on Feb. 19
February 6, 2025
-
COMMENTARY Companies Welcome Generic Drug Fund, but Fret Pricing and Regulations
February 5, 2025
ページ
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…